Zhang T, Zhang Y, Zhou L, et al. - Since prognostic heterogeneity represents a crucial characteristic of patients with non‐small cell lung cancer (NSCLC) with brain metastases (BM), researchers confirmed the applicability of the adjusted Lung‐molGPA model for NSCLC with BM in a Chinese cohort in this multi‐institutional retrospective analysis. This analysis involved 1,903 patients at three hospitals in Southwest China. They compared the Lung‐molGPA model vs the adjusted DS‐GPA (diagnosis‐specific prognostic factor index) model in terms of how well it estimated the survival of NSCLC with BM. Findings revealed that the prognosis of adenocarcinoma patients was better predicted by the adjusted Lung‐molGPA model in comparison with the DS‐GPA model, however, estimating the prognosis for non‐adenocarcinoma patients was not enabled by the adjusted Lung‐molGPA model.